At the beginning of the treatment, free daunomycin seemed able to keep up with the efficacy of the Dau-αMSH treatment; on the other hand, it resulted in high toxicity and lack of tumor inhibition compared to the controls (Figure 7b). Here, STAMBP is linked to neoplasm.